Literature DB >> 20477829

Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids.

Matthias Preusser1, Sabina Plumer, Elisabeth Dirnberger, Johannes A Hainfellner, Christine Mannhalter.   

Abstract

RCL2 is an alcohol-based fixative reported to preserve histomorphology and nucleic acids in non-CNS neoplasms. We compared histomorphology, immunohistochemistry, DNA and RNA in brain tumor specimens preserved frozen at -80°C, and after formalin or RCL2 fixation. RCL2-fixed and paraffin-embedded (RCLPE) samples showed well-preserved histomorphology and specific immunoreactivity comparable to formalin-fixed and paraffin-embedded (FFPE) specimens testing a broad panel of antibodies. In all the analyzed cases, high-molecular weight DNA (up to a fragment length of 600 bp) was amplifyable from RCLPE samples, even after prolonged fixation times. Beta-actin (ACTB) and O6-methylguanine-methyltransferase (MGMT) gene concentrations were significantly higher in DNA isolated from RCLPE specimens as compared with FFPE specimens. Testing of MGMT promoter methylation status using methylation-specific polymerase-chain reaction (MSP) yielded conclusive results in 8/8 analyses in RCLPE and 6/8 analyses in FFPE material, respectively. Amplification of three reference genes (ABL, RAR-alpha, BCR-1) from cDNA showed good RNA preservation in frozen and RCLPE tissue specimens and significant RNA degradation in all FFPE samples. In conclusion, RCL2 fixation of brain tumor biopsies does not seem to significantly compromise histological tumor typing or immunohistochemistry and preserves nucleic acids (DNA and RNA) at a better quality than formalin fixation.
© 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20477829     DOI: 10.1111/j.1750-3639.2010.00400.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  11 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

Review 2.  Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

Authors:  Anna S Berghoff; Johannes A Hainfellner; Christine Marosi; Matthias Preusser
Journal:  CNS Oncol       Date:  2015

3.  The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.

Authors:  Florence Boissière-Michot; Amélie Denouël; Nathalie Boulle; Carole Guillaume; Béatrice Orsetti; Evelyne Lopez-Crapez; Marie-Christine Chateau; Frédéric Bibeau
Journal:  Pathol Oncol Res       Date:  2012-08-15       Impact factor: 3.201

4.  MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.

Authors:  David McCarthy; Walter Pulverer; Andreas Weinhaeusel; Oscar R Diago; Daniel J Hogan; Derek Ostertag; Michelle M Hanna
Journal:  Epigenomics       Date:  2016-06-23       Impact factor: 4.778

5.  A Buffered Alcohol-Based Fixative for Histomorphologic and Molecular Applications.

Authors:  Candice Perry; Joon-Yong Chung; Kris Ylaya; Chel Hun Choi; Amari Simpson; Kaipo T Matsumoto; William A Smith; Stephen M Hewitt
Journal:  J Histochem Cytochem       Date:  2016-05-24       Impact factor: 2.479

6.  Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage.

Authors:  Sergey Mareninov; Jason De Jesus; Desiree E Sanchez; Andrew B Kay; Ryan W Wilson; Ivan Babic; Weidong Chen; Donatello Telesca; Jerry J Lou; Leili Mirsadraei; Tracie P Gardner; Negar Khanlou; Harry V Vinters; Bob B Shafa; Albert Lai; Linda M Liau; Paul S Mischel; Timothy F Cloughesy; William H Yong
Journal:  J Neurooncol       Date:  2013-05-03       Impact factor: 4.130

7.  Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.

Authors:  Matthias Preusser; Anna S Berghoff; Claudia Manzl; Martin Filipits; Andreas Weinhäusel; Walter Pulverer; Karin Dieckmann; Georg Widhalm; Adelheid Wöhrer; Engelbert Knosp; Christine Marosi; Johannes A Hainfellner
Journal:  Clin Neuropathol       Date:  2014 Jan-Feb       Impact factor: 1.368

Review 8.  Tissue fixation and the effect of molecular fixatives on downstream staining procedures.

Authors:  William J Howat; Beverley A Wilson
Journal:  Methods       Date:  2014-02-21       Impact factor: 3.608

9.  Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients--yes, but how?

Authors:  Anna S Berghoff; Matthias Preusser
Journal:  Clin Neuropathol       Date:  2012 Nov-Dec       Impact factor: 1.368

10.  Evaluation of two commercial and three home-made fixatives for the substitution of formalin: a formaldehyde-free laboratory is possible.

Authors:  Cristina Zanini; Elisa Gerbaudo; Elisabetta Ercole; Anna Vendramin; Marco Forni
Journal:  Environ Health       Date:  2012-09-04       Impact factor: 5.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.